新辅助化疗后根治性手术对比同步放化疗治疗IB2/IIA/IIB期鳞状宫颈癌的随机对照试验
这项单中心III期随机对照试验纳入635例IB2、IIA或IIB期鳞状宫颈癌患者,比较紫杉醇卡铂新辅助化疗后根治性手术与顺铂同步放化疗的疗效与毒性。
要点
- 新辅助化疗手术组24个月后迟发性阴道毒性低于同步放化疗组(12.0% vs 25.6%)。
核心结论
- 在局部晚期鳞状宫颈癌中,顺铂同步放化疗较新辅助化疗后根治性手术获得更优的无病生存。
研究设计与样本
- 单中心、III期随机对照试验(NCT00193739),纳入18至65岁IB2、IIA或IIB期鳞状宫颈癌患者。
- 共635例随机分组,633例纳入最终分析(新辅助化疗手术组316例,同步放化疗组317例),中位随访58.5个月。
- 新辅助组接受3周期紫杉醇卡铂(每3周一次)后根治性子宫切除术,术后视指征追加辅助放疗或同步放化疗;同步放化疗组接受标准放疗联合每周顺铂共5周。
主要发现
- 治疗完成24个月或以后的迟发性毒性:直肠毒性分别为2.2%和3.5%,膀胱毒性分别为1.6%和3.5%,阴道毒性分别为12.0%和25.6%。
临床怎么用
- 对于IB2、IIA或IIB期鳞状宫颈癌,顺铂同步放化疗应作为优先考虑的标准治疗。
- 新辅助化疗后根治性手术可作为可选方案,但需告知患者DFS可能较差且迟发性阴道毒性较低。
局限性
- 单中心研究,结果外推需谨慎。
- 原文未报告无进展生存、局部控制率及急性毒性等详细数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. Patients and Methods This was a single-center, phase III, randomized controlled trial ( ClinicalTrials.gov identifier: NCT00193739). Eligible patients were between 18 and 65 years old and had stage IB2, IIA, or IIB squamous cervical cancer. They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks. Patients in the neoadjuvant group received postoperative adjuvant radiation or concomitant chemotherapy and radiotherapy, if indicated. The primary end point was disease-free survival (DFS), defined as survival without relapse or death related to cancer, and secondary end points included overall survival and toxicity. Results Between September 2003 and February 2015, 635 patients were randomly assigned, of whom 633 (316 patients in the neoadjuvant chemotherapy plus surgery group and 317 patients in the concomitant chemoradiation group) were included in the final analysis, with a median follow-up time of 58.5 months. The 5-year DFS in the neoadjuvant chemotherapy plus surgery group was 69.3% compared with 76.7% in the concomitant chemoradiation group (hazard ratio, 1.38; 95% CI, 1.02 to 1.87; P = .038), whereas the corresponding 5-year OS rates were 75.4% and 74.7%, respectively (hazard ratio, 1.025; 95% CI, 0.752 to 1.398; P = .87). The delayed toxicities at 24 months or later after treatment completion in the neoadjuvant chemotherapy plus surgery group versus the concomitant chemoradiation group were rectal (2.2% v 3.5%, respectively), bladder (1.6% v 3.5%, respectively), and vaginal (12.0% v 25.6%, respectively). Conclusion Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer.
引用
- Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018. PMID: 29432076. doi:10.1200/JCO.2017.75.9985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。